Metagenomi, Inc. (MGX)
NASDAQ: MGX · IEX Real-Time Price · USD
-0.86 (-11.10%)
At close: Apr 19, 2024, 4:00 PM
-0.39 (-5.66%)
After-hours: Apr 19, 2024, 4:16 PM EDT

Company Description

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.

The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.

It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies.

The company was incorporated in 2016 and is based in Emeryville, California.

Metagenomi, Inc.
Metagenomi logo
Country United States
Founded 2018
IPO Date Feb 9, 2024
Industry Biotechnology
Sector Healthcare
Employees 236
CEO Brian C. Thomas, Ph.D.

Contact Details

5959 Horton Street, 7th Floor
Emeryville, California 94608
United States
Phone (510) 871-4880

Stock Details

Ticker Symbol MGX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001785279
Employer ID 81-3909017
SIC Code 2836

Key Executives

Name Position
Dr. Brian Charles Thomas Ph.D. Co-Founder, Chief Executive Officer and Chairman of the Board
Dr. Jian Irish M.B.A., Ph.D. President, Chief Operating Officer and Director
Dr. Sarah B. Noonberg M.D., Ph.D. Chief Medical Officer
Dr. Jak Knowles M.D. Co-Founder and Member of Scientific Advisory Board
Pamela M. Wapnick M.B.A. Chief Financial Officer
Dr. Luis G. Borges Ph.D. Chief Scientific Officer
Matthew L. Wein J.D. Vice President of Corporate Legal, Compliance and Corporate Secretary
Dr. Alan Brooks Ph.D. Senior Vice President of Preclinical
Dr. Christopher Brown Head of Discovery

Latest SEC Filings

Date Type Title
Mar 27, 2024 8-K Current Report
Mar 27, 2024 10-K Annual Report
Feb 13, 2024 8-K Current Report
Feb 12, 2024 424B4 Prospectus
Feb 9, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 8, 2024 EFFECT Notice of Effectiveness
Feb 8, 2024 CERT Certification by an exchange approving securities for listing
Feb 7, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Feb 6, 2024 UPLOAD Filing
Feb 5, 2024 8-A12B Registration of securities